ESR1 and ovarian cancer: While a number of ER+ breast cancer models, such as MCF-7 that require in vivo estrogen supplementation (reviewed in41), are routinely used in drug development, future work will need to investigate the effect of estrogen supplementation on ovarian cancer cell biology and response to targeted therapeutics.